{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:49:03Z","timestamp":1791676143546,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07100-2","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:55:12Z","timestamp":1783097712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low- to moderate-dose thalidomide combination rescue after luspatercept failure in transfusion-dependent \u03b2-thalassemia: a real-world cohort study"],"prefix":"10.1007","volume":"105","author":[{"given":"Soulivanh","family":"Nanthachak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoping","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"8","key":"7100_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMra2021838","volume":"384","author":"AT Taher","year":"2021","unstructured":"Taher AT, Musallam KM, Cappellini MD (2021) \u03b2-thalassemias. N Engl J Med 384(8):727\u2013743","journal-title":"N Engl J Med"},{"issue":"18","key":"7100_CR2","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"390","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM et al (2024) Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia. N Engl J Med 390(18):1663\u20131676","journal-title":"N Engl J Med"},{"issue":"3","key":"7100_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK et al (2021) CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med 384(3):252\u2013260","journal-title":"N Engl J Med"},{"issue":"13","key":"7100_CR4","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","volume":"382","author":"MD Cappellini","year":"2020","unstructured":"Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T et al (2020) A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia. N Engl J Med 382(13):1219\u20131231","journal-title":"N Engl J Med"},{"issue":"12","key":"7100_CR5","first-page":"e845","volume":"9","author":"AT Taher","year":"2022","unstructured":"Taher AT, Cappellini MD, Kattamis A, Porter JB, Viprakasit V, Coates T et al (2022) Luspatercept for the treatment of anaemia in non-transfusion-dependent \u03b2-thalassaemia (BEYOND). Lancet Haematol 9(12):e845\u2013854","journal-title":"Lancet Haematol"},{"issue":"5","key":"7100_CR6","first-page":"420","volume":"110","author":"MD Cappellini","year":"2023","unstructured":"Cappellini MD, Porter JB, Viprakasit V, Taher AT et al (2023) Health-related quality of life outcomes from the BELIEVE study. Eur J Haematol 110(5):420\u2013428","journal-title":"Eur J Haematol"},{"issue":"5","key":"7100_CR7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ajh.27255","volume":"99","author":"DL Panzieri","year":"2024","unstructured":"Panzieri DL et al (2024) Real-world efficacy and safety of luspatercept in transfusion-dependent \u03b2-thalassemia. Am J Hematol 99(5):854\u2013863","journal-title":"Am J Hematol"},{"issue":"3","key":"7100_CR8","first-page":"303","volume":"200","author":"KM Musallam","year":"2025","unstructured":"Musallam KM (2025) Luspatercept in transfusion-dependent \u03b2-thalassemia: current evidence and future perspectives. Br J Haematol 200(3):303\u2013312","journal-title":"Br J Haematol"},{"issue":"3","key":"7100_CR9","first-page":"568","volume":"5","author":"L Torti","year":"2024","unstructured":"Torti L et al (2024) Luspatercept in \u03b2-thalassemia: who and when. eJHaem 5(3):568\u2013577","journal-title":"eJHaem"},{"issue":"25","key":"7100_CR10","first-page":"e34154","volume":"103","author":"W Ju","year":"2024","unstructured":"Ju W et al (2024) Efficacy and safety of thalidomide in patients with intermediate\/severe \u03b2-thalassemia. Med (Baltim) 103(25):e34154","journal-title":"Med (Baltim)"},{"key":"7100_CR11","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.2147\/IJGM.S462991","volume":"17","author":"W Zhu","year":"2024","unstructured":"Zhu W et al (2024) Long-term follow-up of thalidomide therapy in transfusion-dependent \u03b2-thalassemia. Int J Gen Med 17:2145\u20132155","journal-title":"Int J Gen Med"},{"key":"7100_CR12","first-page":"110777","volume":"129","author":"K Yang","year":"2020","unstructured":"Yang K et al (2020) Thalidomide for patients with \u03b2-thalassemia: a multicenter trial. Biomed Pharmacother 129:110777","journal-title":"Biomed Pharmacother"},{"key":"7100_CR13","doi-asserted-by":"publisher","first-page":"10521","DOI":"10.1038\/s41598-023-40849-4","volume":"13","author":"Z Ali","year":"2023","unstructured":"Ali Z et al (2023) Long-term clinical efficacy and safety of thalidomide in hydroxyurea-refractory transfusion-dependent \u03b2-thalassemia. Sci Rep 13:10521","journal-title":"Sci Rep"},{"key":"7100_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41392-021-00811-0","volume":"6","author":"JM Chen","year":"2021","unstructured":"Chen JM, Zhu WJ, Liu J, Wang GZ, Chen XQ, Tan Y et al (2021) Safety and efficacy of thalidomide in patients with transfusion-dependent \u03b2-thalassemia: a randomized clinical trial. Signal Transduct Target Ther 6:405","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"7100_CR15","first-page":"1030","volume":"6","author":"SH Ansari","year":"2022","unstructured":"Ansari SH et al (2022) Hydroxyurea plus thalidomide combination therapy reduces transfusion requirement in \u03b2-thalassemia. Blood Adv 6(4):1030\u20131038","journal-title":"Blood Adv"},{"key":"7100_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12920-024-01963-y","volume":"17","author":"WJ Yang","year":"2024","unstructured":"Yang WJ et al (2024) Efficacy of thalidomide across \u03b2-thalassemia genotypes. BMC Med Genomics 17:163","journal-title":"BMC Med Genomics"},{"key":"7100_CR17","first-page":"102098","volume":"103","author":"IU Rahman","year":"2025","unstructured":"Rahman IU et al (2025) Thalidomide improves hemoglobin and hematopoietic gene expression in \u03b2-thalassemia. Blood Cells Mol Dis 103:102098","journal-title":"Blood Cells Mol Dis"},{"key":"7100_CR18","first-page":"441","volume":"20","author":"WJ Yang","year":"2024","unstructured":"Yang WJ et al (2024) Two-year outcomes of low-dose thalidomide therapy in \u03b2-thalassemia. Ther Clin Risk Manag 20:441\u2013451","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"7100_CR19","first-page":"937","volume":"190","author":"PA Mart\u00ednez","year":"2020","unstructured":"Mart\u00ednez PA et al (2020) Smad2\/3-pathway ligand trap luspatercept enhances erythropoiesis. Br J Haematol 190(6):937\u2013947","journal-title":"Br J Haematol"},{"issue":"11","key":"7100_CR20","first-page":"5821","volume":"130","author":"A Verma","year":"2020","unstructured":"Verma A et al (2020) Biological basis for efficacy of activin receptor ligand traps. J Clin Invest 130(11):5821\u20135832","journal-title":"J Clin Invest"},{"issue":"1","key":"7100_CR21","first-page":"30","volume":"201","author":"S Sheth","year":"2023","unstructured":"Sheth S et al (2023) Management of luspatercept therapy in patients with hemoglobinopathies. Br J Haematol 201(1):30\u201342","journal-title":"Br J Haematol"},{"issue":"1","key":"7100_CR22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41392-022-01122-8","volume":"7","author":"Y Tie","year":"2022","unstructured":"Tie Y et al (2022) TGF-\u03b2\/SMAD signal transduction: biology, function and therapy. Signal Transduct Target Ther 7(1):282","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl 1","key":"7100_CR23","first-page":"1783","volume":"141","author":"S Kakkar","year":"2023","unstructured":"Kakkar S et al (2023) Low-dose vs standard-dose thalidomide in transfusion-dependent \u03b2-thalassemia. Blood 141(Suppl 1):1783","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07100-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07100-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07100-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:07:05Z","timestamp":1791673625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07100-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7100"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07100-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of the First Affiliated Hospital of Guangxi Medical University. Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"428"}}